EQ Stock Overview
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Equillium, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.73 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$0.45 |
| Beta | 1.67 |
| 1 Month Change | -35.69% |
| 3 Month Change | 108.63% |
| 1 Year Change | 154.37% |
| 3 Year Change | -70.63% |
| 5 Year Change | -67.84% |
| Change since IPO | -87.64% |
Recent News & Updates
Recent updates
Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues
Mar 27
Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher
Aug 14Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06
Aug 12Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher
May 03Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?
Mar 26Equillium GAAP EPS of -$0.41 in-line
Aug 15Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)
Oct 08Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?
Mar 09Equillium prices $30M registered direct offering
Feb 04Equillium (EQ) Investor Presentation - Slideshow
Dec 04How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?
Nov 24FDA gives green signal to Equillium's late-stage COVID-19 trial
Oct 30Shareholder Returns
| EQ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | -4.7% | -3.7% |
| 1Y | 154.4% | -2.7% | 20.2% |
Return vs Industry: EQ exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: EQ exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| EQ volatility | |
|---|---|
| EQ Average Weekly Movement | 25.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EQ's share price has been volatile over the past 3 months.
Volatility Over Time: EQ's weekly volatility has increased from 16% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 44 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
Equillium, Inc. Fundamentals Summary
| EQ fundamental statistics | |
|---|---|
| Market cap | US$60.99m |
| Earnings (TTM) | -US$13.33m |
| Revenue (TTM) | US$36.08m |
1.7x
P/S Ratio-4.6x
P/E RatioIs EQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EQ income statement (TTM) | |
|---|---|
| Revenue | US$36.08m |
| Cost of Revenue | US$0 |
| Gross Profit | US$36.08m |
| Other Expenses | US$49.42m |
| Earnings | -US$13.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 100.00% |
| Net Profit Margin | -36.96% |
| Debt/Equity Ratio | 0% |
How did EQ perform over the long term?
See historical performance and comparison